Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill
November 06, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
– Top-Line Results Expected by the Fourth Quarter of 2018 – – NDA Submission for LDL-C Lowering Indication for the Bempedoic Acid / Ezetimibe Combination Pill Expected by First Quarter 2019 – ANN...
Esperion to Host Analyst and Investor Day Event on October 17
October 10, 2017 08:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid
October 02, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
– Pivotal Phase 3 Top-Line Results for Bempedoic Acid Expected in the Second and Third Quarters of 2018 –– NDA Submission for LDL-C Lowering Indication for Bempedoic Acid Planned by First Quarter 2019...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 11, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Prices Public Offering of Common Stock
August 09, 2017 21:20 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Announces Proposed Public Offering of Common Stock
August 08, 2017 16:31 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results
August 08, 2017 08:00 ET
|
Esperion Therapeutics, Inc.
– Phase 3 Enrollment Progress Supports NDA Submissions for LDL-C Lowering Indications for Bempedoic Acid / Ezetimibe Combination Pill and Bempedoic Acid by the First Quarter 2019 –– Conference Call...
Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin
August 08, 2017 07:30 ET
|
Esperion Therapeutics, Inc.
– 1002-038 Study Meets Primary Endpoint With a Robust 64% LDL-C Lowering Efficacy –– Clinically Relevant 48% hsCRP Reduction –– The Combination Therapy Was Observed to be Safe and Well-Tolerated ––...
Esperion to Provide Bempedoic Acid Franchise Development Program Updates and Second Quarter Financial Results
August 02, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
– Conference Call and Webcast on Tuesday, August 8, 2017 at 8:30 a.m. Eastern Time – ANN ARBOR, Mich., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid...
Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor
July 26, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 26, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...